scorecard
  1. Home
  2. stock market
  3. news
  4. Moderna pops, then drops after it says booster shot increases protection against Omicron

Moderna pops, then drops after it says booster shot increases protection against Omicron

Matthew Fox   

Moderna pops, then drops after it says booster shot increases protection against Omicron
  • Moderna soared as much as 9% Monday after it said its booster increased protection against Omicron.
  • A third dose of Moderna's vaccine resulted in a 37-fold increase in protection against the variant.
  • Moderna's authorized booster shot is half the dose of each of its first two vaccine shots.
  • Sign up here for our daily newsletter, 10 Things Before the Opening Bell.

Moderna stock soared as much as 9% on Monday after it said its COVID-19-vaccine booster increased protection against the Omicron variant. Shares ultimately gave up those gains and fell by as much as 1% amid a broad stock-market sell-off.

A third dose, which is half the dose of each of the first two vaccine shots, resulted in a 37-fold increase in antibody protection against the fast-spreading Omicron variant, the company said.

"The dramatic increase in COVID-19 cases from the Omicron variant is concerning to all. However, these data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37-fold higher than pre-boost levels are reassuring," Stéphane Bancel, the CEO of Moderna, said.

The results have yet to be peer-reviewed, and Moderna added that its original two-dose vaccine regimen did not provide a strong response to the Omicron variant.

To quickly combat the rise of the Omicron variant, Moderna said it planned to quickly advance an Omicron-specific booster candidate into clinical testing, in case it becomes necessary.

"Given the long-term threat demonstrated by Omicron's immune escape, Moderna will also continue to develop an Omicron-specific variant vaccine (mRNA-1273.529) that it expects to advance into clinical trials in early 2022 and will evaluate including Omicron in its multivalent booster program," Moderna said in a press release Monday.

"We will also continue to generate and share data across our booster strategies with public health authorities to help them make evidence-based decisions on the best vaccination strategies against SARS-CoV-2," Bancel added.

The strong booster results against Omicron are welcome news for Moderna investors, who have experienced a 40% decline since the stock topped out around $497 in August. The stock reversed its gains to losses on Monday morning, falling about 1%. Still, shares of Moderna are up 187% year to date.

READ MORE ARTICLES ON



Popular Right Now



Advertisement